Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 601–670 of 670
Commentary: Social class, C-reactive protein and coronary heart disease
Casas, J. P. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn025 · Cited by 1
Das, U. N. (2010) · Wiley eBooks · doi:10.1002/9780813820637.ch6 · Cited by 1
Maru, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-56024-1_16 · Cited by 1
Landis, R. C., Buckley, C. D., Évora, P. R. B., & Hart, D. A. (2013) · International Journal of Inflammation · doi:10.1155/2013/468287 · Cited by 1
“This minority viewpoint, however, chimes with other advocates who have argued consistently that certain nagging gaps remain to be explained in understanding the role of inflammation on AMI outcomes [8, 9].”
BackgroundKumar, A., Scroggie, S., Sarkar, T. D., Hepokoski, M., & Malhotra, A. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561067 · Cited by 1
“Furthermore, GLP-1RAs and concomitant weight loss may impact hsCRP levels, which importantly is not only a marker of inflammation, but may also mediate inflammation via complement pathways, worsening myocardial infarct size in pre-clinical models [15].”
CRP, Uric Acid, and Other Novel Factors in the Pathogenesis of Hypertension
Feig, D. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-824-9_5 · Cited by 1
Pathophysiology of Type 2 Diabetes Mellitus with Particular Reference to Hypothalamus
Das, U. N. (2010) · Wiley eBooks · doi:10.1002/9780813820637.ch12
Novel Risk Factors for Type II Diabetes Mellitus and Coronary Heart Disease
Dehghan, A. (2010) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
Effects of C-Reactive Protein on the Cardiac Differentiation of Mouse Embryonic Stem Cells
Jin, Y., Cao, J., Xu, X. P., Ye, X., Chen, Y. G., Yang, J., Feng, Q., Zhu, L., Xi, Q., & Yang, C. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00311
Multifactorial aspects of antibody-mediated blood cell destruction
Kapur, R. (2014) · UvA-DARE (University of Amsterdam)
Zickler, D. (2010) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12172
Anti-CD20 therapy for heart attack
Haas, M. J. (2013) · Science-Business eXchange · doi:10.1038/scibx.2013.1015
Inflammation, insulin resistance, and cardiovascular disease: Cause or correlate?
Sattar, N. A. (2008) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-008-0011-6
Jain, J., Narang, U., Jain, V., & Gupta, O. (2013) · Heart Views · doi:10.4103/1995-705x.126882
“[4] hs-CRP an acute phase reactant has been linked to the development of an acute plaque and standardized strong predictor of CAD and future cardiovascular events.[5,6] Thus, the present prospective study was aimed to evaluate efficacy of STS and hs-CRP as a prognostic indicator in patients of more than 18 years of ag…”
C-Reactive Protein in Estimating Inflammatory Status in Patients with Acute Coronary Syndrome
Dimitrijević, O., Stojcevski, B. D., Svetlana, I., & Majkić-Singh, N. (2008) · Journal of Medical Biochemistry · doi:10.2478/v10011-007-0045-1
“However, ongoing works show that specific inhibitors of CRP, such as 1,6-bis(phosphocholin)-hexane, can be beneficial in the treatment of cardiovascular diseases (22).”
BackgroundC-reactive protein as a marker of cardiovascular risk. Chicken, egg or turkey?
Karet, B. (2008) · Primary Care Cardiovascular Journal (PCCJ) · doi:10.3132/pccj.2008.036
Established and Novel Biomarkers in ST-elevation Myocardial Infarction
Waks, J. W., & Scirica, B. M. (2011) · Future Cardiology · doi:10.2217/fca.11.31
Padilla, N. D., Boekholdt, S. M., Lagrand, W. K., Niessen, H. W. M., & Hack, C. E. (2012)
Hogue, J. (2008) · Corpus Université Laval (Université Laval) · Cited by 1
Can CRP affect the blood-brain barrier during acute ischemic stroke?
Bielewicz, J., Kurzepa, J., Czekajska−Chehab, E., Kamieniak, P., Daniluk, B., & Bartosik-Psujek, H. (2015) · Polish Journal of Public Health · doi:10.1515/pjph-2015-0033
“It affects blood/brain stability [11] and exacerbates the injuries of tissues in ischemic necrosis during a stroke [12].”
BackgroundBorges, M. F. P. J. P. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Drogan, D. (2009) · DepositOnce · doi:10.14279/depositonce-2080
“Spezifische Substanzen zur Reduktion erhöhter CRPKonzentrationen wurden bislang erst in Tiermodellen erprobt [223].”
BackgroundCRP Blocker Shows Benefit for MI — in Rats
Komaroff, A. L. (2006) · Journal watch · doi:10.1056/jw200605160000004
Attia, A., Zaghla, H. E., Badran, H. M., Alhaddad, O., & Rewisha, E. A. (2011) · Egyptian Liver Journal · doi:10.1097/01.elx.0000397036.56165.3c
Insulin-Like Signaling and Tissue-Specific Requirements of Anoxia Survival in Caenorhabditis elegans
Pavlyukovskyy, M. (2009) · The Eagle Feather · doi:10.12794/tef.2009.157
Plaque Passivation and Endothelial Therapy
Thompson, P. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-4927-2.00026-8
Stabilizing unstable plaque in acute coronary syndromes
Thompson, A., & Thompson, P. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7295-3927-2.10045-4
Neurobiology of Postischemic Recuperation in the Aged Mammalian Brain
Popa‐Wagner, A., Balseanu, A., Zăgrean, L., Shah, I. M., Napoli, M. D., Ahlenius, H., & Kokaia, Z. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195326697.003.0017
Dimitri, H. R. (2012) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
PREECLAMPSIA: THE ROLES OF ACUTE INFLAMMATION AND INTRAUTERINE STRESS
Parchim, N. F. (2016) · Digital Commons-TMC (Texas Medical Center)
PROGNOSTIC SIGNIFICANCE OF C-REACTIVE PROTEIN IN ACUTE STROKE
James, P., Mangalasundaram, R., & Radhakrishnan, A. N. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/818
C-Reactive Protein and Cardiovascular Disease in Psoriasis
Goldminz, A. M., & Gottlieb, A. B. (2011) · Psoriasis Forum · doi:10.1177/247553031117a00103
Susekov, A. V., Zubareva, M. Y., Ta, R., & Масенко, В. П. (2011) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2011-6-81-88
“В частности, сообщили, что применение маленькой молекулы, названной 1,6 бис (фосфохолин) гексан, которая связывает и ингибирует человеческий CPБ, в эксперименте уменьшала распространенность ИМ у крыс [19].”
Elbattawy, W. A., Rauf, S. A., & Nasr, S. S. (2020) · Egyptian Dental Journal /Egyptian Dental Journal · doi:10.21608/edj.2020.39482.1211
Ekaidem, E., I.S., I. S., ab, A., Udoh, U. H., I.F.c, I. F. C., Usoroh, U., & A.J.a, A. J. A. (2020) · International Journal of Research Publications · doi:10.47119/ijrp100571720201341
“High level of CRP has been associated with point mutation cys 130 Aug in Apo E gene, coding for apolipoprotein E, thus establishing a link between lipid values and inflammatory markers modulation [15,16,17].”
BackgroundA Major Cause of Death in COPD and Risk Factors for Lung Cancer—a Dilemma or a Mistake?
Au, D. H., Chien, J. W., & Bryson, C. L. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.176.6.625
Cardiovascular Disease and Inflammation
Jankowska, M., Lindholm, B., & Stenvinkel, P. (2021) · Springer eBooks · doi:10.1007/978-3-319-90760-4_23-1
Das, U. N. (2011) · Springer eBooks · doi:10.1007/978-94-007-0495-4_7
Ponticelli, C. (2007) · CRC Press eBooks · doi:10.3109/9780203089903-11
Mold, C., Sun, P. D., & Clos, T. W. D. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0024236
(2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2068
Hussen, A. H., Alaarag, A. F., Abdalaal, M., & Alsaed, A. M. (2022) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2022/v11i430213
““Additionally, CRP is no longer merely considered a marker but also recognised as an atherosclerosis mediator” [9,10].”
BackgroundLafta, M. A., & Abdulzahra, I. S. (2023) · journal of the college of basic education · doi:10.35950/cbej.v21i88.9960
Sieczkowska, S. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-08082023-163811
Pinyorospathum, C. (2018) · Chula Digiverse · doi:10.58837/chula.the.2018.92
Zykov, M. V., Butsev, V. V., Trubnikova, O. A., & Барбараш, О. Л. (2024) · Russian neurological Journal · doi:10.30629/2658-7947-2024-29-4-36-46
Chen, H., Wang, M., Yang, L., Li, J., & Li, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s494487
“32,33 There is ample evidence to support that high levels of hsCRP are associated with poor prognosis in stroke patients.”
Identification of Prognostic Factors for Sepsis or Septic Shock Patients with Cardiac Dysfunction
Tian, J., Liu, Y., Zhao, Y., Wang, Z., & Wang, L. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10645-8
“The insertion of MAC into cardiomyocyte membranes induces osmotic lysis [37, 38].”
Orihashi, R., Fujino, N., & Mizoguchi, Y. (2025) · Archives of Gerontology and Geriatrics Plus · doi:10.1016/j.aggp.2025.100233
Involvement of Interleukin-33/ST2 in Myocardial Dysfunction in Murine Model of Sepsis
Choe, Y. (2012) · Scholarship@Western (Western University)
Chan, J. E., Mann, A. K., Kapp, D. S., & Rehkopf, D. H. (2020) · Figshare · doi:10.6084/m9.figshare.13294892
Chan, J. E., Mann, A. K., Kapp, D. S., & Rehkopf, D. H. (2020) · Figshare · doi:10.6084/m9.figshare.13294889
Chan, J. E., Mann, A. K., Kapp, D. S., & Rehkopf, D. H. (2020) · Figshare · doi:10.6084/m9.figshare.13294898
Ueba, H., Shiomi, M., Brines, M. L., Yamin, M., Kobayashi, T., Ako, J., Momomura, S.-I., Cerami, A., & Kawakami, M. (2013) · Figshare · doi:10.6084/m9.figshare.7194041
Chan, J. E., Mann, A. K., Kapp, D. S., & Rehkopf, D. H. (2020) · Figshare · doi:10.6084/m9.figshare.13294895
Wani, S., Kulkarni, S., Pingale, P. L., Rane, B. R., Bachhav, Y. G., & Dua, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34003-1.00009-2
A colorimetric paper-based immunosensor for high-sensitivity C-reactive protein (hs-CRP) detection
Lawanstien, D., Ngernpradab, P., & Srisa‐Art, M. (2026) · Analytical Methods · doi:10.1039/d5ay01911g
La réponse immunitaire allogénique contre les cellules souches cardiaques humaines
Hocine, H. R. (2016) · theses.fr (ABES) · doi:10.70675/b67461f7za40ez447dz9448za581c0182ef0
Allogeneic cardiac stem/progenitor cells and innate immune and humoral responses
Noémie, T. N. Q. D. (2018) · theses.fr (ABES) · doi:10.70675/db25e4a0z54f4z4749zb745zbd99ce1aaa9b
Klotz, S. A., Sobonya, R. E., & Lipke, P. N. (2026) · Pathogens · doi:10.3390/pathogens15040436
Henning, A. (2026) · FreiDok plus (Universitätsbibliothek Freiburg) · doi:10.6094/unifr/282779
Monomeric C-reactive Protein as a Mediator of Chronic Inflammation in Obesity
Pentek, A., & Bacârea, A. (2026) · Cureus · doi:10.7759/cureus.108410 · Cited by 1
CRP (C-Reactive Protein) Revisited: An Old Yet New Biomarker of Acute and Chronic Inflammation
Nagasawa, M. (2026) · Cells · doi:10.3390/cells15110998 · Cited by 2
“In an acute kidney injury model, administration of pCRP exacerbated kidney injury; however, this exacerbation was suppressed by administration of 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which inhibits the conversion of pCRP to mCRP [69].”
Jiang, Y., & Li, W.-Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-59867-z · Cited by 1
Pentraxins and Atherosclerosis
Barbati, E., Bottazzi, B., Catapano, A. L., Garlanda, C., Latini, R., Mantovani, A., Norata, G. D., & Valentino, S. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0338-8_11
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.